access to services and transplantation. Prior to developing a protocol for attempted eradication of Bcc, similar to that applied to *Pseudomonas aeruginosa*, UK CF centres were surveyed to establish what practices are currently employed.

Methods A questionnaire was distributed to CF centre directors and non-returns followed up by email reminder.

Results Responses were obtained from 35 units (73%). Because of the rarity of new Bcc infection in paediatric centres, only replies from 16 adult centres (representing 3400 patients) have been analysed further. 12 centres, representing 2860 patients, always attempt eradication of newly isolated Bcc. Two additional centres attempt eradication only in the presence of additional indications. Only two units had a formal eradication policy. IV antibiotics were used in all cases, for a median of 2 (range 2–6) weeks, typically comprising combined tobramycin and meropenem with additional therapy consisting of septrin (n=5), ceftazidime (6), and chloramphenicol (2). Nebulised antibiotics (typically tobramycin or meropenem) were also used in 13 of these 14 centres. Five units used additional oral antibiotics, for a median of 7 (2–12) weeks. This most commonly involved minocycline (n=4) and/or septrin (n=5). Two thirds of adult centres estimated success rate of eradication therapy to be <50%. In centres where eradication was not routine, factors that dissuaded clinicians were perceived poor success of treatment (n=5), toxicity (n=3), cost (n=1) and lack of experience with this approach (n=2).

Conclusions Attempted eradication of newly acquired Bcc is controversial, involving expensive and potentially toxic therapies with no evidence to guide treatment choice and no published outcome data. Despite this, it is common practice in many UK adult CF centres. Most units do not have a formal eradication policy, adopting a variety of approaches, and estimates of treatment success are pessimistic. Since new acquisition of Bcc is now relatively rare, it is hard for even large units to assess response to therapies. A systematic approach is required to optimise and standardise treatment regimens, and assess outcomes.

P169 CHARACTERISTICS AND SURVIVAL OF PATIENTS WITHOUT CYSTIC FIBROSIS (CF), ISOLATING MUCOID *P AERUGINOSA* (MPA) IN SPUTUM SAMPLES

doi:10.1136/thoraxjnl-2011-201054c.169

R Ahmed, M Denton, I Clifton, D Peckham. Leeds Teaching Hospitals NHS Trust, Leeds, UK

Introduction and Objectives It is well established in patients with CF mPA indicates chronic infection and is associated with increased morbidity and mortality. Mucoïd PA can be isolated in people with non-CF lung disease but to-date no study has systematically characterised these patients. The aim of this study was to characterise and evaluate the significance of mucoïd strain in a large non CF population.

Methods This study retrospectively examined the demography, clinical diagnoses and survival, of patients without CF with an initial isolate of mPA from their respiratory samples, between January 2008 and December 2010, in Leeds. Data were obtained from the microbiology and radiology databases, and from the clinical notes. Ethical approval was obtained.

Results A total of 170 patients isolated mPA in sputum for the first time during the study period. The median (range) age was 73 (22–99) years and 54% were female. 46% of patients had samples obtained during an in-patient stay. 21% of the patients had never seen a respiratory physician. The majority of patients had a diagnosis of bronchiectasis (See Abstract P169 figure 1). A third of patients had isolated non-mucoïd PA prior to isolating mPA. 62% of the patients had a subsequent respiratory sample analysed and the majority continued to grow mPA. 24 patients also grew Methicillin-resistant *Staphylococcus aureus* (MRSA) from their sputum. The

median age (range) of death was 78 (40–95) years. The cumulative survival was 50% at 3 years after isolating mPA. Factors associated with increased mortality included co-isolation of MRSA, no previous respiratory review, isolating mPA during in-patient care and absence of bronchiectasis ($p < 0.05$).

Abstract P169 Figure 1 Diagnosis of patients isolating mPA.

Conclusions Mucoïd *P aeruginosa* isolated from the sputum of patients without CF may persist and is associated with high mortality. The underlying respiratory diagnosis of patients isolating mPA includes a range of respiratory diseases. There may be an opportunity to eradicate *P aeruginosa* in patients who grow non-mucoïd PA before the emergence of mPA.

P170 A COST-EFFECTIVENESS ANALYSIS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS IN INFANTS IN THE UK

doi:10.1136/thoraxjnl-2011-201054c.170

¹A Bentley, ²I Filipovic, ²K Gooch, ²K Buesch. ¹Abacus International, Bicester, UK; ²Abbott Laboratories, Solna, Sweden

Background and Aim RSV is the most common cause of lower respiratory tract infection in young children and may result in hospitalisations, long-term sequelae, such as recurrent wheeze and/or asthma, and possibly death. Palivizumab is a prophylaxis against severe RSV infection and has been shown to reduce RSV-related hospitalisations, and provides a preventative option for high-risk infants. The aim of this study is to demonstrate the cost-effectiveness of RSV prophylaxis compared to no prophylaxis in the following high-risk infants groups: infants with chronic lung disease (CLD) and premature babies (<29, 29–32 and 33–35 weeks gestational age (wGA)).

Methods A decision-tree model was developed to reflect the clinical pathway of infants at high-risk of severe RSV infection. Baseline risk of RSV-hospitalisations and efficacy data were taken from palivizumab clinical trials and published meta-analysis. Cost data were obtained from national databases and published literature using an NHS perspective. The main outcome was presented as the incremental costs per Quality-Adjusted Life-Year (QALY) gained (ICER). The base-case analysis considered a lifetime horizon to capture the impact of long-term morbidity and mortality associated with RSV hospitalisations.

Results Prophylaxis against severe RSV infection resulted in ICERs of £19 168, £18 174 & £1185 per QALY for high-risk infants with, CLD and the premature infant groups, <29 wGA and 29–32 wGA respectively compared to no prophylaxis. All results are below the accepted NICE threshold of £30 000 /QALY thus demonstrating cost-effectiveness. The baseline ICER for the 33–35 wGA subgroup was above this threshold however, sensitivity analysis considering risk-factors in this subgroup showed that an increase in baseline risk of hospitalisation, from 7.2% to 11.24%, led to palivizumab becoming a cost-effective option.